Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST)

May 11, 2021 updated by: University Hospital of North Norway

Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST). A Randomised-controlled Trial of Thrombolytic Treatment With Tenecteplase for Acute Ischaemic Stroke Upon Awakening

Stroke is a leading causes of death and disability. At least 20% of strokes occur during sleep, so- called 'wake up stroke'. Thrombolysis with the clot-busting drug alteplase is effective for acute ischaemic stroke, provided that it is given within 4.5 hours of symptom onset. Patients with wake-up stroke are currently ineligible for clot-busting therapy. Previous studies indicate that many wake-up strokes occur just before awakening.

In this study, patients with wake-up stroke will be randomized to thrombolysis with tenecteplase and best standard treatment or to best standard treatment without thrombolysis. Tenecteplase has several potential advantages over alteplase, including very rapid action and that it can be given as a single injection. Prior to thrombolysis, a brain scan must be done to exclude bleeding or significant brain damage as a result from the stroke. We will use a CT scan to inform this decision. CT is used as a routine examination in all stroke patients. Other studies testing clot-busting treatment in wake-up stroke are using alteplase and more complex brain scans, which are not routinely available in the emergency situation in all hospitals.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Background:

One in five strokes occur during sleep, but patients with "wake-up" stroke are not given thrombolytic therapy because time of stroke onset is unknown. On-going trials are testing alteplase, and use MRI techniques for selection of patients. Tenecteplase has many pharmacological advantages over alteplase: greater fibrin specificity, very rapid action, longer half-life, and single bolus administration. In addition, patient selection based on MRI findings risks excluding many patients that might otherwise benefit. TWIST will test tenecteplase and will not use MRI techniques for selection of patients. Plain CT and CT angiography (if possible) will be performed before randomisation, and CT perfusion will be performed at selected centres, as part of a sub-study.

Study design: TWIST is an international, multi-centre, randomised, open-label, blinded-endpoint trial of tenecteplase for acute ischaemic 'wake-up' stroke.

Study questions:

  1. Can tenecteplase given <4.5 hours of awakening improve functional outcome at 3 months?
  2. Can findings on cerebral plain CT and CT angiography (and CT perfusion, at selected centres) identify patients who benefit from such treatment, compared to other patients?

Patients eligible for treatment who are able to receive tenecteplase within 4.5 hours of waking, will be randomly allocated to treatment with tenecteplase in addition to best standard treatment, versus best standard treatment.

Randomisation and treatment: Central randomisation (over the internet) to tenecteplase 0.25 mg/mg i.v. (maximum dose 25 mg) plus best medical treatment vs. best medical treatment alone.

Imaging: All patients will undergo CT and CT angiography (CTA, if possible) before randomisation and on day 2. CT perfusion (CTP) will be performed at selected centres, as part of a sub-study.

Follow-up and primary effect variable: Centralised follow-up via telephone or mail at 3 months. The primary effect variable is functional outcome (modified Rankin Scale score).

Study size and centers: 600 patients from centers in Norway, Sweden, Denmark, Finland, Estonia, Latvia, Lithuania, United Kingdom, Switzerland and New Zealand.

Study Type

Interventional

Enrollment (Anticipated)

600

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • København, Denmark, 2400
      • Odense, Denmark
      • Pärnu, Estonia, 80010
        • Recruiting
        • Parnu Hospital
        • Contact:
        • Principal Investigator:
          • Katrin Antsov, MD
      • Tallin, Estonia, 10617
        • Recruiting
        • West Tallin Central Hospital
        • Contact:
        • Principal Investigator:
          • Katrin Gross-Paju, MD
      • Tallinn, Estonia, 10138
        • Recruiting
        • East Tallin Central Hospital
        • Contact:
        • Principal Investigator:
          • Toomas Toomsoo, MD
      • Tartu, Estonia, 51014
      • Helsinki, Finland
        • Recruiting
        • Helsinki University Hospital
        • Contact:
      • Joensuu, Finland
        • Recruiting
        • Siun sote - Joint municipal authority for North Karelia social and health services
        • Contact:
          • Sirpa Kaipiainen, MD
        • Principal Investigator:
          • Jussi Sipilä, MD
      • Kouvola, Finland
        • Recruiting
        • Pohjois-Kymen sairaala
        • Contact:
      • Vaasa, Finland, 65130
        • Recruiting
        • Central Hospital in Vaasa
        • Contact:
        • Principal Investigator:
          • Jukka Saarinen, MD
    • Satakunta
      • Pori, Satakunta, Finland, 28500
        • Recruiting
        • Satakunta Central Hospital
        • Contact:
        • Principal Investigator:
          • Juha Puustinen, MD
      • Riga, Latvia
        • Not yet recruiting
        • Riga East University Hospital
        • Contact:
          • Aleksejs Višņakovs
        • Principal Investigator:
          • Guntis Karelis, MD
      • Alytus, Lithuania, 62114
        • Recruiting
        • Alytus S. Kudirkos Hospital
        • Contact:
        • Principal Investigator:
          • Juknelis Kestutis, MD
      • Kaunas, Lithuania, 50009
        • Recruiting
        • Lithuanian University of Health Sciences Kauno klinikos
        • Contact:
        • Principal Investigator:
          • Daiva Rastenyte, MD
      • Klaipėda, Lithuania
        • Recruiting
        • Klaipeda Seamen's Hospital
        • Contact:
        • Principal Investigator:
          • Robertas Urbutis, MD
      • Vilnius, Lithuania, LT-04130
      • Vilnius, Lithuania, LT-08661
        • Recruiting
        • Vilnius University Hospital
        • Contact:
      • Christchurch, New Zealand
        • Recruiting
        • Christchurch Hospital
        • Contact:
        • Principal Investigator:
          • Teddy Wu, MD, PhD
      • Arendal, Norway, 4838
        • Terminated
        • Sørlandet sykehus HF Arendal
      • Drammen, Norway, N-3004
        • Not yet recruiting
        • Drammen sykehus Vestre Viken HF
        • Contact:
        • Principal Investigator:
          • Karl-Friedrich Amthor, MD
      • Flekkefjord, Norway, N-4400
        • Recruiting
        • Sørlandet Sykehus HF Flekkefjord
        • Contact:
        • Principal Investigator:
          • Rita Van Lessen, MD
      • Førde, Norway, N-6807
        • Recruiting
        • Helse Førde HF
        • Contact:
        • Principal Investigator:
          • Magdalena Stankiewicz, MD
      • Gravdal, Norway, N-8372
        • Recruiting
        • Nordlandssykehuset Lofoten Gravdal
        • Contact:
        • Principal Investigator:
          • Bettina Heermann, MD
      • Hammerfest, Norway, N-9601
      • Harstad, Norway, 9480
        • Recruiting
        • University Hospital of North Norway, Harstad
        • Contact:
        • Principal Investigator:
          • Maria Fjellstad, MD
      • Kirkenes, Norway, N-9900
      • Kristiansand, Norway, N-4604
        • Recruiting
        • Sørlandet sykehus Kristiansand HF
        • Contact:
        • Contact:
        • Principal Investigator:
          • Arnstein Tveiten, MD, PhD
      • Levanger, Norway, N-7601
        • Terminated
        • Sykehuset Levanger
      • Lørenskog, Norway, N-1478
        • Recruiting
        • Akershus universitetssykehus (Ahus)
        • Contact:
        • Principal Investigator:
          • Antje Reichenbach, MD
      • Mosjøen, Norway, N-8651
        • Withdrawn
        • Helgelandssykehuset Mosjøen
      • Narvik, Norway, N-8504
        • Recruiting
        • University Hospital of North Norway, Narvik
        • Contact:
        • Principal Investigator:
          • Arne Haavik, MD
      • Sandvika, Norway, N-1346
        • Recruiting
        • Bærum sykehus Vestre Viken HF
        • Contact:
        • Principal Investigator:
          • Håkon Ihle-Hansen, MD
      • Skien, Norway, N-3710
        • Recruiting
        • Sykehuset Telemark Skien
        • Contact:
        • Principal Investigator:
          • Håkon Tobro, MD
      • Stavanger, Norway, N-4068
        • Active, not recruiting
        • Stavanger Universitetssjukehus
      • Tromsø, Norway, N-9019
        • Recruiting
        • University Hospital of North Norway, Tromsø
        • Contact:
        • Contact:
        • Principal Investigator:
          • Agnethe Eltoft, MD, PhD
      • Trondheim, Norway, N-7006
        • Recruiting
        • St Olavs hospital
        • Contact:
        • Contact:
        • Principal Investigator:
          • Gitta Rohweder, MD
      • Ålesund, Norway, N-6026
        • Recruiting
        • Ålesund sjukehus Helse Møre og Romsdal
        • Contact:
        • Principal Investigator:
          • Yngve M Seljeseth, MD
      • Göteborg, Sweden, 413 45
        • Recruiting
        • Sahlgrenska Universitetssjukhuset
        • Contact:
      • Hässleholm, Sweden, 281 25
      • Karlstad, Sweden, 65230
        • Recruiting
        • Central Hospital Karlstad
        • Contact:
        • Principal Investigator:
          • Felix Andler, MD
      • Lund, Sweden
        • Not yet recruiting
        • Skane University Hospital Lund
        • Contact:
          • Gunnar Andsberg, MD
        • Principal Investigator:
          • Gunnar Andsberg, MD
      • Malmö, Sweden, 221 85
        • Recruiting
        • Skane University Hospital Malmo
        • Contact:
      • Skövde, Sweden, 541 85
        • Recruiting
        • Skaraborg Hospital Skovde
        • Contact:
        • Principal Investigator:
          • Björn Cederin, MD
      • Solna, Sweden, 171 76
        • Withdrawn
        • Karolinska Sjukhuset
      • Stockholm, Sweden, 112 81
        • Not yet recruiting
        • Saint Goran Hospital
        • Contact:
        • Principal Investigator:
          • Jan Mathé, MD
      • Stockholm, Sweden, 18288
        • Recruiting
        • Danderyd Hospital
        • Contact:
        • Principal Investigator:
          • Elisabet Rooth, MD
      • Uppsala, Sweden, 751 85
        • Recruiting
        • Akademiska Sjukhuset
        • Contact:
      • Ängelholm, Sweden, 26281
        • Recruiting
        • Ängelholm Hospital
        • Contact:
        • Principal Investigator:
          • Björn Hedström, MD
      • Basel, Switzerland, 4031
        • Recruiting
        • University Hospital Basel
        • Contact:
      • Nyon, Switzerland
        • Recruiting
        • Groupement Hospitalier Ouest Lémanique
        • Contact:
        • Principal Investigator:
          • Julien Niederhauser, MD
      • Aberdeen, United Kingdom, AB25 2ZN
        • Not yet recruiting
        • Aberdeen Royal Infirmary
        • Principal Investigator:
          • Mary Joan Macleod, MD
        • Contact:
      • Birkenhead, United Kingdom
        • Recruiting
        • Arrowe Park
        • Contact:
        • Principal Investigator:
          • Ruth Davis, MD
      • Birmingham, United Kingdom
        • Recruiting
        • University Hospital Birmingham
        • Contact:
        • Principal Investigator:
          • Mark Willmot, MD
      • Bournemouth, United Kingdom, BH7 7DW
        • Not yet recruiting
        • Royal Bournemoth and Christchurch Hospital
        • Contact:
        • Principal Investigator:
          • Oliver Hopper, MD
      • Cambridge, United Kingdom, CB2 0QQ
      • Chester, United Kingdom, CH2 1UL
        • Recruiting
        • Countess Of Chester Hospital NHS Foundation Trust
        • Contact:
        • Principal Investigator:
          • Kausik Chatterjee, MD
      • Coventry, United Kingdom
        • Recruiting
        • University Hospitals Coventry & Warwickshire
        • Contact:
        • Principal Investigator:
          • Usman Ghani, MD
      • Derby, United Kingdom, DE 22 3 NE
        • Recruiting
        • Royal Derby Hospital
        • Contact:
        • Principal Investigator:
          • Timothy England, MD
      • Edinburgh, United Kingdom, EH16 4SA
        • Not yet recruiting
        • Royal Infirmary of Edinburgh Hospital
        • Contact:
        • Principal Investigator:
          • William Whiteley, MD
      • Exeter, United Kingdom, EX2 5DW
        • Recruiting
        • Royal Devon and Exeter Hospital
        • Contact:
        • Principal Investigator:
          • Martin James, MD
      • Gloucester, United Kingdom
        • Recruiting
        • Gloucestershire Royal Hospital
        • Contact:
        • Principal Investigator:
          • Dipankar Dutta, MD
      • Halifax, United Kingdom
        • Recruiting
        • Calderdale Royal Infirmary
        • Contact:
        • Principal Investigator:
          • Anand Nair, MD
      • Kingston upon Hull, United Kingdom
        • Recruiting
        • Hull University Teaching Hospital
        • Contact:
        • Principal Investigator:
          • Emma Clarkson, MD
      • Leeds, United Kingdom
        • Recruiting
        • Leeds General Infirmary
        • Contact:
        • Principal Investigator:
          • Vasileios Papavasileiou, MD
      • Leicester, United Kingdom, LE1 5WW
        • Recruiting
        • Leicester Royal Infirmary
        • Contact:
        • Contact:
      • Liverpool, United Kingdom
        • Not yet recruiting
        • Royal Liverpool University Hospital
        • Contact:
        • Principal Investigator:
          • Aravind Manoj, MD
      • London, United Kingdom, NW1 2BU
        • Recruiting
        • University College London
        • Contact:
        • Principal Investigator:
          • Richard Perry, MD
      • London, United Kingdom
        • Recruiting
        • Royal London Hospital
        • Contact:
        • Principal Investigator:
          • Rachel Evans, MD
      • London, United Kingdom, W6 8RF
        • Recruiting
        • Charing Cross Hospital
        • Contact:
        • Principal Investigator:
          • Omid Halse, MD
      • London, United Kingdom, SE5 9RS
        • Recruiting
        • King´s College Hospital
        • Contact:
        • Principal Investigator:
          • Lalit Kalra, MD
      • London, United Kingdom, SW17 0QT
        • Recruiting
        • St Georges Hospital
        • Contact:
        • Principal Investigator:
          • Barry Moynihan, MD
      • Luton, United Kingdom
        • Recruiting
        • Luton and Dunstable University Hospital
        • Contact:
        • Principal Investigator:
          • Sakthivel Sethuraman, MD
      • Morriston, United Kingdom, SA6 6NL
        • Recruiting
        • Morriston Hospital
        • Contact:
        • Principal Investigator:
          • Mushtaq Wani, MD
      • Newcastle Upon Tyne, United Kingdom, NE1 4LP
        • Recruiting
        • Royal Victoria Infirmary
        • Contact:
        • Principal Investigator:
          • Anand Dixit, MD
      • Nottingham, United Kingdom, NG5 1PB
        • Recruiting
        • Nottingham City Hospital
        • Contact:
        • Principal Investigator:
          • Philip Bath, MD
      • Salford, United Kingdom
      • Southampton, United Kingdom
        • Recruiting
        • Southhampton General Hospital
        • Contact:
        • Principal Investigator:
          • Richard Marigold, MD
      • Stoke-on-Trent, United Kingdom
        • Recruiting
        • Royal Stoke University Hospital
        • Contact:
        • Principal Investigator:
          • Girish Muddegowda, MD
      • Taunton, United Kingdom
        • Recruiting
        • Musgrove Park Hospital
        • Contact:
        • Principal Investigator:
          • Dumin Karunatilake, MD
      • Yeovil, United Kingdom, BA21 4AT
        • Recruiting
        • Yeovil District Hospital
        • Principal Investigator:
          • Khalid Rashed, MD
        • Contact:
    • Mid Yorkshire
      • Wakefield, Mid Yorkshire, United Kingdom, WF1 4DG
        • Recruiting
        • Pinderfields Hospital
        • Contact:
        • Principal Investigator:
          • Michael Carpenter, MD
    • Northumberland
      • Cramlington, Northumberland, United Kingdom
    • Massachusetts
      • Worcester, Massachusetts, United States, 01655
        • Not yet recruiting
        • University of Massachusetts Medical School
        • Contact:
        • Principal Investigator:
          • Brian Silver, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Stroke symptoms on awakening that were not present before sleep
  • Clinical diagnosis of stroke with limb weakness with NIHSS score >=3, or dysphasia
  • Treatment with tenecteplase is possible within 4.5 hours of awakening
  • Written consent from the patient, non-written consent from the patient (witnessed by non-participating health care personnel), or written consent from the nearest family member

Exclusion Criteria:

  • Age <18 years
  • NIHSS score >25 or NIHSS consciousness score >2, or seizures during stroke onset
  • Findings on plain CT that indicate that the patient is unlikely to benefit from treatment:

    • Infarction comprising more than >1/3 of the middle cerebral artery territory on plain CT or CT perfusion
    • Intracranial haemorrhage, structural brain lesions which can mimic stroke (e.g cerebral tumour)
  • Active internal bleeding of high risk of bleeding, e.g.:

    • Major surgery, trauma or gastrointestinal or urinary tract haemorrhage within the previous 21 days, or arterial puncture at a non-compressible site within the previous 7 days
    • Any known defect in coagulation, e.g. current use of vitamin K antagonist with an INR >1.7 or prothrombin time >15 seconds, or use of direct thrombin inhibitors or direct factor Xa inhibitors during the last 24 hours (unless reversal of effect can be achieved by agents such as idarucizumab) or with elevated sensitive laboratory tests (such as activated partial thromboplastin time (aPTT), international normalized ratio (INR), platelet count, ecarin clotting time, thrombin time (TT), or appropriate factor Xa activity assays), or heparins during the last 24 hours or with an elevated aPTT greater than the upper limit of normal
    • Known defect of clotting or platelet function or platelet count below 100,000/mm3 (but patients on antiplatelet agents can be included)
    • Ischaemic stroke or myocardial infarction in previous 3 months, previous intracranial haemorrhage, severe traumatic brain injury or intracranial or intraspinal operation in previous 3 months, or known intracranial neoplasm, arteriovenous malformation or aneurysm
  • Contraindications to tenecteplase, e.g., acute bacterial endocarditis or pericarditis; acute pancreatitis; severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension; active hepatitis; systemic cancer with increased bleeding risk; haemostatic defect including secondary to severe hepatic, renal disease; organ biopsy; prolonged cardiopulmonary resuscitation > 2 min (within 2 weeks)
  • Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), despite blood pressure lowering treatment
  • Blood glucose <2.7 or >20.0 mmol/L (use of finger-stick measurement devices is acceptable)
  • Pregnancy, positive pregnancy test, childbirth during last 10 days, or breastfeeding. In any woman of childbearing potential, a pregnancy test must be performed and the result assessed before trial entry
  • Other serious or life-threatening disease before the stroke: severe mental or physical disability (e.g. Mini Mental Status score <20, or mRS score ≥3), or life expectancy less than 12 months
  • Patient unavailability for follow-up (e.g. no fixed address)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Tenecteplase
Tenecteplase + Best standard treatment
Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
Other Names:
  • Metalyse
Other: Control
No tenecteplase + Best standard treatment
Best standard treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional outcome at 3 months.
Time Frame: 3 months
Functional outcome will be assessed by the modified Rankin Scale (mRS), values 0-6
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Symptomatic intracranial haemorrhage during the first 7 days.
Time Frame: First 7 days
  1. Symptoms (neurological deterioration, new headache, new acute hypertension, new nausea or vomiting, or sudden decrease in conscious level).
  2. Intracranial haemorrhage on brain MRI or CT.
First 7 days
Asymptomatic intracranial haemorrhage during the first 7 days.
Time Frame: First 7 days
Intracranial haemorrhage on brain MRI or CT without: neurological deterioration, new headache, new acute hypertension, new nausea or vomiting or sudden decrease in consciousness level.
First 7 days
Recurrent ischaemic stroke during the first 7 days
Time Frame: First 7 days
Neurological deterioration (increase of ≥2 on NIHSS, after exclusion of other causes for neurological deterioration) occurring after 72 hours will be considered as a recurrent stroke. A recurrent stroke will be classified as ischaemic if imaging has excluded haemorrhage.
First 7 days
Death from all cause
Time Frame: First 7 days

Death will be classified according to cause:

  1. Initial stroke
  2. Recurrent stroke
  3. Myocardial infarction
  4. Pneumonia
  5. Other
First 7 days
Death from all cause
Time Frame: 3 months

Death will be classified according to cause:

  1. Initial stroke
  2. Recurrent stroke
  3. Myocardial infarction
  4. Pneumonia
  5. Other
3 months
Barthel Index score
Time Frame: 3 months
Ordinal scale for measuring performance in activities of daily living
3 months
EuroQol Score (EQ-5D)
Time Frame: 3 months
Measure of health-related quality of life
3 months
Mini Mental State Examination
Time Frame: 3 months
30-point questionnaire for measurement of cognitive impairment
3 months
Health-economic variables
Time Frame: 3 months
Costs related to length of hospital stay, nursing home care after discharge, re-hospitalisations during first 3 months
3 months
Functional outcome at 3 months
Time Frame: 3 months
Functional outcome assessed by dichotomized mRS; values 0-1 vs 2-6.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Ellisiv B Mathiesen, University Hospital of North Norway

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 12, 2017

Primary Completion (Anticipated)

December 31, 2021

Study Completion (Anticipated)

December 31, 2022

Study Registration Dates

First Submitted

June 6, 2017

First Submitted That Met QC Criteria

June 6, 2017

First Posted (Actual)

June 8, 2017

Study Record Updates

Last Update Posted (Actual)

May 14, 2021

Last Update Submitted That Met QC Criteria

May 11, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 2015/1070/REC North
  • 2014-000096-80 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ischemic Stroke

Clinical Trials on Tenecteplase

Search Similar Trials